Terms: = Ovarian cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
14 results:
1. clinical outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract] [Full Text] [Related]
2. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.
Zong S; Xu PP; Xu YH; Guo Y
J Ovarian Res; 2022 Aug; 15(1):90. PubMed ID: 35915456
[TBL] [Abstract] [Full Text] [Related]
3. Expression of ACAP1 Is Associated with Tumor Immune Infiltration and clinical outcome of ovarian cancer.
Zhang J; Zhang Q; Zhang J; Wang Q
DNA Cell Biol; 2020 Sep; 39(9):1545-1557. PubMed ID: 32456571
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.
Necchi A; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Ross JS; Jacob JM
Eur Urol Focus; 2019 Sep; 5(5):748-755. PubMed ID: 31147264
[TBL] [Abstract] [Full Text] [Related]
5. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
[TBL] [Abstract] [Full Text] [Related]
6. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.
Ocaña A; Pérez-Peña J; Alcaraz-Sanabria A; Sánchez-Corrales V; Nieto-Jiménez C; Templeton AJ; Seruga B; Pandiella A; Amir E
Oncotarget; 2016 Apr; 7(16):22865-72. PubMed ID: 26992217
[TBL] [Abstract] [Full Text] [Related]
7. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S; Sasajima Y; Kasamatsu T; Oda-Otomo R; Okada S; Ishikawa M; Ikeda S; Kato T; Tsuda H
Pathol Oncol Res; 2015 Apr; 21(2):487-94. PubMed ID: 25370301
[TBL] [Abstract] [Full Text] [Related]
8. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract] [Full Text] [Related]
9. KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
Heublein S; Grasse K; Hessel H; Burges A; Lenhard M; Engel J; Kirchner T; Jeschke U; Mayr D
BMC Cancer; 2013 Oct; 13():483. PubMed ID: 24139521
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells.
Mern DS; Hasskarl J; Burwinkel B
Br J Cancer; 2010 Oct; 103(8):1237-44. PubMed ID: 20842131
[TBL] [Abstract] [Full Text] [Related]
11. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.
Wolf AM; Rumpold H; Reimer D; Marth C; Zeimet AG; Wolf D
Gynecol Oncol; 2010 Sep; 118(3):244-50. PubMed ID: 20603238
[TBL] [Abstract] [Full Text] [Related]
12. Breast cancer treatment--later pregnancy and survival.
Kasum M
Eur J Gynaecol Oncol; 2006; 27(3):225-9. PubMed ID: 16800246
[TBL] [Abstract] [Full Text] [Related]
13. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract] [Full Text] [Related]
14. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer.
Kusume T; Tsuda H; Kawabata M; Inoue T; Umesaki N; Suzuki T; Yamamoto K
Clin Cancer Res; 1999 Dec; 5(12):4152-7. PubMed ID: 10632354
[TBL] [Abstract] [Full Text] [Related]
